Immunome IMNM Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunome's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunome's accretion (amortization) of discounts and premiums, investments?
- Immunome (IMNM) reported accretion (amortization) of discounts and premiums, investments of $0 in Q1 2026.
- How has Immunome's accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Immunome's accretion (amortization) of discounts and premiums, investments decreased by 100.0% year-over-year, from $818K to $0.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This represents the non-cash adjustment to interest income or expense resulting from the amortization of premiums or discounts on debt securities held as investments. It reflects the gradual alignment of the security's carrying value with its par value over the remaining term to maturity. Investors use this to understand the effective yield of the company's investment portfolio beyond nominal coupon payments.